Retraction
TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathologic Complete Response to Pertuzumab and Trastuzumab in Breast Cancer
Paper Information
Record ID:
28623
Author(s):
Roisin M Connolly
Jeffrey P Leal
Lilja Solnes
Chiung Yu Huang
Ashley Carpenter
Katy Gaffney
Vandana Abramson
Lisa A Carey
Minetta C Liu
Mothaffar Rimawi
Jennifer Specht
Anna Marie Stornniolo
Vicente Valero
Christos Vaklavas
Ian E Krop
Eric P Winer
Melissa Camp
Robert S Miller
Antonio C Wolff
Ashley Cimino-Mathews
Ben H Park
Richard L Wahl
Vered Stearns
Jeffrey P Leal
Lilja Solnes
Chiung Yu Huang
Ashley Carpenter
Katy Gaffney
Vandana Abramson
Lisa A Carey
Minetta C Liu
Mothaffar Rimawi
Jennifer Specht
Anna Marie Stornniolo
Vicente Valero
Christos Vaklavas
Ian E Krop
Eric P Winer
Melissa Camp
Robert S Miller
Antonio C Wolff
Ashley Cimino-Mathews
Ben H Park
Richard L Wahl
Vered Stearns
Journal:
Publication Date:
February 05, 2019
Retraction Date:
May 17, 2021
(4.5 years years ago)
Subjects:
Broad Categories:
Medicine
Medicine
Institutions:
- Johns Hopkins University School of Medicine, Baltimore, MD Vanderbilt University, Nashville, TN
- University of North Carolina, Chapel Hill, NC
- Mayo Clinic, Rochester, MN
- Baylor College of Medicine, Houston, TX
- 6University of Washington, Seattle, WA Indiana University, Indianapolis, IN
- The University of Texas MD Anderson Cancer Center, Houston, TX
- University of Alabama at Birmingham, Birmingham, AL
- Dana-Farber Cancer Institute, Boston, MA
- Washington University in St Louis, St Louis, MO
Country:
🇺🇸 United StatesArticle Type:
Publisher:
American Society of Clinical Oncology
Open Access:
No
PubMed ID:
Retraction PubMed ID:
Retraction Details
Retraction Reasons:
Nature of Retraction:
Retraction
Retraction Notice:
10.1200/JCO.21.00752Additional Notes:
see https://ascopubs.org/doi/10.1200/JCO.21.00280?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed
Citations (45)
45
Total Citations18
Post-Retraction(40.0%)
25
Pre-Retraction1
Same DayPost-Retraction Citation Analysis
4
Within 30 days
9
Within 1 year
4
After 2+ years
1045
Days since retraction (latest)
Paper citing TBCRC026: Phase II Trial Correlating Standardized ...
Unknown Authors
Unknown Journal
Published: Unknown
Repeatability of 18F-FDG uptake in metastatic bone lesions of breast cancer patients and implications for accrual to clinical trials
Mark Muzi, Lanell M. Peterson, Jennifer M. Specht et al. (11 authors)
EJNMMI Research
Open Access
Published: Mar 2024
2 citations
2 citations
1045 days after retraction
Repeatability of 18F-FDG uptake in metastatic bone lesions of breast cancer patients and implications for accrual to clinical trials
Mark Muzi, Lanell M. Peterson, Jennifer M. Specht et al. (11 authors)
Research Square (Research Square)
Open Access
Published: Jan 2024
1 citation
1 citation
974 days after retraction
Assessment of novel prognostic biomarkers to predict pathological complete response in patients with non-metastatic triple-negative breast cancer using a window of opportunity design
C.R. Akshatha, Dhanapathi Halanaik, Rajesh Nachiappa Ganesh et al. (8 authors)
Therapeutic Advances in Medical Oncology
Open Access
Published: Jan 2024
2 citations
2 citations
959 days after retraction
Impact of Imaging Biomarkers and AI on Breast Cancer Management: A Brief Review
Gehad A. Saleh, Nihal M. Batouty, Abdelrahman Gamal et al. (15 authors)
Cancers
Open Access
Published: Oct 2023
21 citations
21 citations
896 days after retraction
Using the<i>HER2/CEP17</i>FISH Ratio to Predict Pathologic Complete Response Following Neoadjuvant Anti-HER2 Doublet Therapy in HER2+ Breast Cancer
Eric Lander, Katherine Rappazzo, Li‐Ching Huang et al. (7 authors)
The Oncologist
Open Access
Published: Dec 2022
6 citations
6 citations
572 days after retraction
Automated lesion detection of breast cancer in [18F] FDG PET/CT using a novel AI-Based workflow
Jeffrey P. Leal, Steven P. Rowe, Vered Stearns et al. (10 authors)
Frontiers in Oncology
Open Access
Published: Nov 2022
7 citations
7 citations
547 days after retraction
A sparse-readout quantitative PET scanner for breast cancer therapy optimization
Paul E. Kinahan, William C. Hunter, Kyle Champley et al. (10 authors)
Unknown Journal
Published: Jul 2022
422 days after retraction
Post-Neoadjuvant Treatment in HER2-Positive Breast Cancer: Escalation and De-Escalation Strategies
Natalia Krawczyk, Tanja Fehm, Eugen Ruckhaeberle et al. (8 authors)
Cancers
Open Access
Published: Jun 2022
2 citations
2 citations
397 days after retraction
How Parental Predictors Jointly Affect the Risk of Offspring Congenital Heart Disease: A Nationwide Multicenter Study Based on the China Birth Cohort
Man Zhang, Yongqing Sun, Xiaoting Zhao et al. (10 authors)
Frontiers in Cardiovascular Medicine
Open Access
Published: Jun 2022
6 citations
6 citations
382 days after retraction
Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
Nigel Bundred, Núria Porta, Adrian Murray Brunt et al. (23 authors)
Clinical Cancer Research
Open Access
Published: Feb 2022
9 citations
9 citations
273 days after retraction
Application of Noninvasive Imaging to Combined Immune Checkpoint Inhibitors for Breast Cancer: Facts and Future
Zhongquan Cheng, Yang Du, Leyi Yu et al. (5 authors)
Molecular Imaging and Biology
Published: Jan 2022
5 citations
5 citations
259 days after retraction
New standards for phantom image quality and SUV harmonization range for multicenter oncology PET studies
Go Akamatsu, Naoki Shimada, Keīichi Matsumoto et al. (10 authors)
Annals of Nuclear Medicine
Published: Jan 2022
10 citations
10 citations
242 days after retraction
Quantitative Imaging in Oncologic PET
Richard L. Wahl, Martin A. Lodge
Unknown Journal
Published: Nov 2021
179 days after retraction
Neoadjuvant Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in Patients With ERBB2-Positive Breast Cancer
Thomas Hatschek, Theodoros Foukakis, Judith Bjöhle et al. (26 authors)
JAMA Oncology
Open Access
Published: Jun 2021
47 citations
47 citations
38 days after retraction
Advances in PET/CT Imaging
Igor Iskra, Dimitris Visvikis, Michel Koole et al. (13 authors)
Unknown Journal
Open Access
Published: Jun 2021
2 citations
2 citations
28 days after retraction
Performance Characteristics of a Dual-Sided Position-Sensitive Sparse-Sensor Detector for Gamma-Ray Imaging
William C. Hunter, Donald Q. Dewitt, Robert S. Miyaoka
IEEE Transactions on Radiation and Plasma Medical Sciences
Open Access
Published: Jun 2021
4 citations
4 citations
22 days after retraction
Management of Early-Stage Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
Sònia Pernas, Sara M. Tolaney
JCO Oncology Practice
Published: Jun 2021
28 citations
28 citations
15 days after retraction
Tailoring Therapy to Be Just Right in HER2-Positive Early-Stage Breast Cancer: The Goldilocks Problem
Joshua Z. Drago, Komal Jhaveri
JCO Oncology Practice
Open Access
Published: Jun 2021
1 citation
1 citation
15 days after retraction
Updated Results of TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathological Complete Response to Pertuzumab and Trastuzumab in Breast Cancer
Roisín M. Connolly, Jeffrey P. Leal, Lilja B. Sólnes et al. (23 authors)
Journal of Clinical Oncology
Open Access
Published: May 2021
34 citations
34 citations
Same day as retraction
Quantitation of cancer treatment response by 2-[18F]FDG PET/CT: multi-center assessment of measurement variability using AUTO-PERCIST™
Joo Hyun O, Su Jin Lim, Hao Wang et al. (6 authors)
EJNMMI Research
Open Access
Published: Feb 2021
4 citations
4 citations
94 days before retraction
Quantitation of cancer treatment response by 2-[18F]FDG PET/CT: multi-center assessment of measurement variability using AUTO-PERCIST™
O Joo‐Hyun, Su Jin Lim, Hao Wang et al. (6 authors)
Research Square (Research Square)
Open Access
Published: Jan 2021
111 days before retraction
Recent advances in neoadjuvant therapy for breast cancer
David A. Potter, César A Herrera-Ponzanelli, Diego Hinojosa Ugarte et al. (8 authors)
Faculty Reviews
Open Access
Published: Jan 2021
16 citations
16 citations
133 days before retraction
PET/MRI for Primary Breast Cancer: A Match Made Better by PET Quantification?
David A. Mankoff, Suleman Surti
Radiology Imaging Cancer
Open Access
Published: Jan 2021
1 citation
1 citation
136 days before retraction
PET Diagnosis and Response Monitoring in Oncology
Richard L. Wahl, Rodney J. Hicks
Elsevier eBooks
Open Access
Published: Jan 2021
2 citations
2 citations
136 days before retraction
Trastuzumab emtansine (T-DM1) as adjuvant treatment of HER2-positive early breast cancer: safety and efficacy
Chiara Molinelli, Francesca Parisi, Maria Grazia Razeti et al. (9 authors)
Expert Review of Anticancer Therapy
Published: Nov 2020
14 citations
14 citations
171 days before retraction
Quantitation of Cancer Treatment Response by FDG PET/CT: Multi-center Assessment of Measurement Variability Using AUTO-PERCISTTM
O Joo‐Hyun, Su Jin Lim, Hao Wang et al. (6 authors)
Research Square (Research Square)
Open Access
Published: Oct 2020
208 days before retraction
Multi-omics analyses identify HSD17B4 methylation-silencing as a predictive and response marker of HER2-positive breast cancer to HER2-directed therapy
Satoshi Yamashita, Naoko Hattori, Satoshi Fujii et al. (14 authors)
Scientific Reports
Open Access
Published: Sep 2020
18 citations
18 citations
236 days before retraction
Application of 99mTc-3PRGD2 Imaging for Early Prediction of Pathological Response to Neoadjuvant Chemotherapy in Breast Tumors and Axillary Lymph Nodes
Zhenying Chen, Fangmeng Fu, Junyu Lin et al. (7 authors)
Research Square (Research Square)
Open Access
Published: Sep 2020
237 days before retraction
Beyond Chemotherapies: Recent Strategies in Breast Cancer Treatment
Arthur Foulon, Pierrick Theret, Lise Rodat‐Despoix et al. (4 authors)
Cancers
Open Access
Published: Sep 2020
11 citations
11 citations
243 days before retraction
Evolving standards of care and new challenges in the management of HER2‐positive breast cancer
Grace Choong, Grace Cullen, Ciara C. O’Sullivan
CA A Cancer Journal for Clinicians
Open Access
Published: Aug 2020
136 citations
136 citations
271 days before retraction
De-escalation of neoadjuvant therapy for HER2-positive early breast cancer: an overview
Gustavo Werutsky, Mahira Lopes Rosa
Annals of Palliative Medicine
Open Access
Published: Jun 2020
2 citations
2 citations
340 days before retraction
Utilizing novel fluorothymidine PET imaging in a phase I study of veliparib on an intermittent and continuous schedule given in combination with carboplatin in metastatic breast cancer
Robert Wesolowski, Daniel G. Stover, Maryam B. Lustberg et al. (29 authors)
medRxiv (Cold Spring Harbor Laboratory)
Open Access
Published: Jan 2020
479 days before retraction
The QIBA Profile for FDG PET/CT as an Imaging Biomarker Measuring Response to Cancer Therapy
Paul E. Kinahan, Eric S. Perlman, John J. Sunderland et al. (10 authors)
Radiology
Open Access
Published: Jan 2020
70 citations
70 citations
496 days before retraction
A high mitotic score in breast cancer after neoadjuvant chemotherapy is predictive of outcome and associated with a distinct morphology
Karen R. Arispe Angulo, Zeeshan Jawa, Alexis Visotcky et al. (6 authors)
Histopathology
Published: Dec 2019
4 citations
4 citations
516 days before retraction
Proceedings of the World Molecular Imaging Congress 2019, Montreal Quebec, Canada September 4-7, 2019: Late-Breaking Abstracts
Jia Li, Marina Stukova, Daniel Rubins et al. (4 authors)
Molecular Imaging and Biology
Open Access
Published: Nov 2019
545 days before retraction
Emerging strategies in neoadjuvant treatment of patients with HER2-positive early breast cancer
Nadia Harbeck
The Breast
Published: Nov 2019
6 citations
6 citations
563 days before retraction
<p>Pertuzumab in the treatment of HER2-positive breast cancer: an evidence-based review of its safety, efficacy, and place in therapy</p>
Kei Ishii, Nao Morii, Hiroyasu Yamashiro
Core evidence
Open Access
Published: Oct 2019
75 citations
75 citations
594 days before retraction
Complete metabolic response with letrozole and palbociclib in advanced breast cancer
Manikandan Dhanushkodi, Balasubramanian Ananthi, Priya Iyer
International Journal of Molecular and Immuno Oncology
Open Access
Published: Sep 2019
611 days before retraction
Breast Cancer Biomarkers: Challenges in Routine Estrogen Receptor, Progesterone Receptor, and HER2/neu Evaluation
Julie M. Jorns
Archives of Pathology & Laboratory Medicine
Open Access
Published: Aug 2019
21 citations
21 citations
654 days before retraction
Reply to E. Hindié et al
Roisín M. Connolly, Chiung‐Yu Huang, Vered Stearns et al. (4 authors)
Journal of Clinical Oncology
Open Access
Published: Jun 2019
1 citation
1 citation
689 days before retraction
Interim [<sup>18</sup>F]Fluorodeoxyglucose–Positron Emission Tomography During Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
Elif Hindié, David Groheux
Journal of Clinical Oncology
Published: Jun 2019
1 citation
1 citation
689 days before retraction
Implications of Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
Antonio C. Wolff, Nadine Tung, Lisa A. Carey
Journal of Clinical Oncology
Open Access
Published: Jun 2019
13 citations
13 citations
714 days before retraction
PET/CT for Patients With Breast Cancer: Where Is the Clinical Impact?
Gary A. Ulaner
American Journal of Roentgenology
Published: May 2019
119 citations
119 citations
741 days before retraction
Early PET response predicts complete response
Peter Sidaway
Nature Reviews Clinical Oncology
Open Access
Published: Feb 2019
1 citation
1 citation
815 days before retraction
Quick Stats
Total Citations:
45
Years Since Retraction:
4.5 years
Open Access:
No
Last Checked:
Jul 24, 2025